NanoKnife System shows strong results in prostate cancer treatment study

NEW YORK - AngioDynamics, Inc. (NASDAQ:ANGO), a medical device company with a market capitalization of $371 million, announced that its NanoKnife System demonstrated positive outcomes in treating intermediate-risk prostate cancer patients, according to results from the PRESERVE study published in European Urology. InvestingPro data shows the company maintains a strong balance sheet, with more cash than debt and robust liquidity metrics.

The peer-reviewed study, conducted across 17 clinical sites in collaboration with the Society of Urologic Oncology Clinical Trials Consortium, enrolled 121 patients with intermediate-risk prostate cancer. At 12 months post-procedure, 84% of men were free from clinically significant disease in the treated area. According to InvestingPro analysis, while the company is currently working toward profitability, it maintains a healthy current ratio of 2.21, indicating strong ability to meet short-term obligations.

The NanoKnife System, which received FDA clearance for prostate tissue ablation in late 2024, uses irreversible electroporation (IRE) technology to ablate targeted prostate tissue without thermal energy, potentially preserving critical structures.

The study showed notable quality-of-life preservation, with 96% of patients maintaining urinary continence at 12 months compared to 97% at baseline. Additionally, 84% of patients with good baseline sexual function maintained sufficient erectile function for penetration at the one-year mark.

"The PRESERVE data supports the long-term data that we are seeing in practice, patients are benefiting from effective, targeted treatment without compromising their quality of life," said Dr. Jonathan Coleman, a urologic surgeon at Memorial Sloan Kettering Cancer Center and co-principal investigator of the study.

The technology offers an alternative to traditional whole-gland treatments for prostate cancer, which is the second most common cancer among men in the United States. With analyst consensus showing bullish sentiment and the stock currently appearing undervalued according to InvestingPro Fair Value analysis, investors seeking detailed insights can access comprehensive Pro Research Reports covering this and 1,400+ other US stocks through InvestingPro’s advanced analytics platform.

The NanoKnife System works by delivering high-voltage pulses that create permanent nanopores in cell membranes, inducing cellular death in the targeted tissue without damaging surrounding structures.

The information in this article is based on a press release from AngioDynamics.

In other recent news, AngioDynamics reported its fiscal fourth-quarter 2025 earnings, revealing a notable performance with net sales of $80.2 million, surpassing analyst expectations of $74.5 million. This result reflects a 12.7% year-over-year growth. The company’s Med Tech segment saw a 22.0% increase in sales to $35.8 million, while the Med Device segment experienced a 6.2% rise to $44.4 million. AngioDynamics also achieved an earnings per share of -$0.03, better than the projected -$0.12. Following these results, H.C. Wainwright maintained its Buy rating with a $16.00 price target for the company. Canaccord Genuity also raised its price target from $15.00 to $17.00, citing a well-executed quarter. Lake Street Capital Markets initiated coverage with a Buy rating and a $24.00 price target, highlighting the company’s strategic realignment. These developments underscore the company’s improving fundamentals and strategic positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.